Enveric Biosciences (ENVB) Change in Cash (2011 - 2026)
Enveric Biosciences (ENVB) posted Change in Cash of $231278.0 for Q1 2026, down 74.86% sequentially from $919897.0 in Q4 2025, and down 88.74% YoY from $2.1 million in Q1 2025.
Enveric Biosciences (ENVB) Change in Cash (2011 - 2026) Analysis & Trends
Enveric Biosciences has reported Change in Cash for 16 years, with the latest figure at $231278.0 in Q1 2026.
- Quarterly Change in Cash fell 88.74% year-over-year to $231278.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $614334.0 (up 129.8% YoY) and the FY2025 annual result came in at $2.4 million, up 5289.38% from the prior year.
- Change in Cash declined to $231278.0 in Q1 2026 per ENVB's latest filing, from $919897.0 in the prior quarter.
- Over five years, Change in Cash peaked at $4.3 million in Q1 2022 and troughed at -$5.5 million in Q2 2023.
- A 5-year average of -$732190.0 and a median of -$870657.0 in 2024 frame the typical range for Change in Cash.
- The sharpest annual moves came in 2023 and 2025: Change in Cash slumped 218.98% in 2023, then jumped 332.25% in 2025.
- Over 5 years, Change in Cash stood at -$3.5 million in 2022, then surged by 43.1% to -$2.0 million in 2023, then jumped by 56.0% to -$870657.0 in 2024, then surged by 205.66% to $919897.0 in 2025, then plunged by 74.86% to $231278.0 in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered $231278.0, $919897.0, and $907778.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | 3.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 231,278.00 |
| Dec 31, 2025 | 919,897.00 |
| Sep 30, 2025 | 907,778.00 |
| Jun 30, 2025 | -1.44 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | -870,657.00 |
| Sep 30, 2024 | -390,868.00 |
| Jun 30, 2024 | -2.85 Mn |
| Mar 31, 2024 | 4.07 Mn |
| Dec 31, 2023 | -1.98 Mn |
| Sep 30, 2023 | -2.81 Mn |
| Jun 30, 2023 | -5.48 Mn |
| Mar 31, 2023 | -5.16 Mn |
| Dec 31, 2022 | -3.48 Mn |
| Sep 30, 2022 | 3.19 Mn |
| Jun 30, 2022 | -3.69 Mn |
| Mar 31, 2022 | 4.34 Mn |
| Dec 31, 2021 | -4.09 Mn |
| Sep 30, 2021 | 830,509.00 |
| Jun 30, 2021 | -2.04 Mn |